Traiter la dépression grâce à la neuromodulation par ultrasons. Basée sur 25 ans de recherche, Sonomind propose une nouvelle approche thérapeutique visant un traitement rapide non-invasif et efficace afin que la dépression ne soit plus une fatalité. Voir nos dernières actualités Ils parlent de notre technologie La dépression 1ère cause d’invalidité dans le monde 300...
Location: France
Total raised: $3.51M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.09.2025 | Seed | $3.51M | Bpifrance |
Mentions in press and media 2
| Date | Title | Description |
| 24.09.2025 | Sonomind Raises €3M in Funding | Sonomind, a Paris, France-based company developing a medical device for non-invasive, personalized ultrasound-based brain stimulation, raised €3M in funding. The round consisted of a €2M ($2.35M) in seed capital from Critical Path Ventures.... |
| - | Sonomind | “Treat depression through ultrasonic neuromodulation. Based on 25 years of research, Sonomind offers a new therapeutic approach aimed at a rapid non-invasive and effective treatment so that depression is no longer inevitable. They p” |